Loading...
Standard Biotool Q1 2025 Earnings Report
Standard BioTools reported first quarter 2025 financial results with a decrease in revenue but an improvement in net loss and adjusted EBITDA.
Key Takeaways
Standard BioTools delivered a solid first quarter in line with expectations, with revenue of $40.8 million, a 10% decrease year-over-year. Despite the revenue decline, the company significantly reduced its operating loss by 45% and improved adjusted EBITDA by 29% year-over-year, reflecting focused execution and cost reductions.
First quarter 2025 revenue was $40.8 million, a 10% decrease compared to the first quarter of 2024.
Operating loss was reduced by 45% year-over-year, and adjusted EBITDA improved by 29% year-over-year.
The company operationalized an additional $10 million in annual run rate cost reductions, bringing the total to $90 million since the merger.
Standard BioTools maintains a strong balance sheet with $261 million in cash and cash equivalents and no material debt as of March 31, 2025.
Standard Biotool
Standard Biotool
Standard Biotool Revenue by Segment
Revenue by Segment
Instruments Revenue
CapyFin.comConsumables Revenue
CapyFin.comField services & other Revenue
CapyFin.com Forward Guidance
For fiscal year 2025, Standard BioTools continues to expect revenue in the range of $165 million to $175 million.
Positive Outlook
- Strategic foothold in proteomics and momentum building for SomaScan and SOMAmers.
- Advantages and performance over legacy antibody-based approaches are well-documented.
- Upcoming launch of Illumina partnered NGS-based product expected to expand access.
- Population-based proteomics studies continue to favor the company's technology.
- Expect momentum to accelerate, ushering in a new era of proteomic discovery.
Challenges Ahead
- Anticipated high single-digit millions decline in Americas academic revenue due to NIH funding pressures.
- No expected effect from U.S. export controls.
- Limited impact from tariffs.
- Challenging Life Sciences macro backdrop.
- Assumes no significant unforeseen negative market or operational impacts.
Revenue & Expenses
Visualization of income flow from segment revenue to net income